"This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment."
From the clinical trials website. Presumably this wasn't powered for efficacy - therefore, is very nice to see the dose-dependent results reach statistical signifcance as likely means a larger biological effect than oringinally thought. Anyone have the trial design specifics with stats in it?????
Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-24
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 555 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 14.45pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable